Saturday 17 October 2026
Export ZVSA’s income statement to Excel — free account
ZyVersa Therapeutics, Inc.
ZVSA Healthcare Biotechnology
In the quarter to March 2026, EPS grew 69.9% and free cash flow grew 54.9%, each against the same quarter a year earlier.
0.05
0.00
0.00%
Follow ZVSA
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.04 | 0.08 | 0.04 | 0.05 |
Net Debt/EBITDA |
0.04 | 0.03 | 0.18 | 0.23 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.69 | 0.07 | 0.61 | 0.45 | |
Interest Coverage |
(15.72) | (157.93) | (4.17) | (9.85) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.95 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.32) | (0.18) | (0.07) | (0.10) | |
Cash per Share |
0.02 | 0.07 | 0.02 | 0.04 | |
Shareholders Equity per Share |
1.27 | (1.51) | (2.08) | (1.74) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.27 | (1.51) | (2.08) | (1.74) | |
Free Cash Flow |
(1.52) | (1.41) | (0.41) | (0.80) | |
Working Capital |
(12.14) | (11.77) | (12.39) | (14.12) | |
Net Current Asset Value |
(12.99) | (11.77) | (12.39) | (14.12) | |
| Other line items | |||||
Quick Ratio |
0.01 | 0.04 | 0.01 | 0.02 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.32) | (0.18) | (0.07) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
9.05 | 9.54 | 9.73 | 9.92 | |
Average Assets |
19.56 | 10.23 | 10.53 | 10.86 | |
Average Common Equity |
7.36 | (2.35) | (1.94) | (3.00) |
Columns are period end dates